

# Molecular Pathology of Gynaecologic Cancer



## Coordinator

Lerma Puertas, Enrique FGS  
elerma@santpau.cat

## Members

Bagué, Silvia FGS  
Espinosa Mariscal, Iñigo FGS  
Gallardo Alcañiz, Alberto FGS  
García-Valdecasas Vilanova,  
Bárbara FGS  
González Vidal, Alan FGS  
López Vilaró, Laura FGS  
Muñoz Beatove, Josefina FGS  
Pons Pérez, Cristina FGS  
Prat Díaz de Losada, Jaime FGS  
Szafranska, Justyna FGS

## Main Lines of Research

- ▶ Pathogenic mechanisms of cancer (endometrial/ovarian cancer and others).
- ▶ Molecular mechanisms of stromal response and immunosuppression in endometrial cancer.
- ▶ Clinical application of prognostic factors in common cancers.
- ▶ Clinical application of tumour markers.
- ▶ Molecular biology of uterine and extra-uterine sarcomas.

## Challenges

- ▶ Cooperate with other groups at the national and international levels.

## Collaborations

### Collaborations with other IIB Sant Pau Groups

- ▶ Experimental Immunology (Silvia Vidal).
- ▶ Estudio de las alteraciones del metabolismo intracelular del colesterol en el cáncer de mama y carcinoma epitelial de tiroides: Evaluación de estrategias terapéuticas basadas en la HDL. (Juan Carlos Escolà Gil). PI16/00139. Instituto de Salud Carlos III. Duration: 2017-2020.
- ▶ Endocrinology, Diabetes and Nutrition (Dra. Rosa Corcoy)

### External Collaborations

Molecular alterations related with progression in endometrial cancer (Spanish Association Against Cancer, AECC):

- ▶ Dr. Jaume Reventós. Vall d'Hebron Hospital Research Institute (VHIR), Barcelona, Spain.
- ▶ Dr. Xavier Matias-Guiu. Institute for Biomedical Research (IRB Lleida), Lleida, Spain.
- ▶ Dr. Miguel Abal. Santiago de Compostela University Hospital Complex (CHUS), Spain.
- ▶ Dr. Gema Moreno. Fundación MD Anderson Internacional, Madrid, Spain.

## Active Grants

- ▶ Jaime Prat Díaz De Losada. Red Temática de Investigación Cooperativa en Cáncer (RTICC). RD12/0036/0011. Instituto de Salud Carlos III. Duration: 2013-2017. 160,000.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

\*TIF: 77.0210 \*\*MIF: 7.0019

Espinosa I., Lee C.-H., D'Angelo E., Palacios J., Prat J., Undifferentiated and Dedifferentiated Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis (2017) *AM J SURG PATHOL*, 41 (8), 1121-1128.

**IF: 5.878**

Espinosa I., Serrat N., Zannoni G.F., Rovira R., D'Angelo E., Prat J., Endometrioid endometrial carcinomas with microcystic, elongated, and fragmented (MELF) type of myoinvasion: role of immunohistochemistry in the detection of occult lymph node metastases and their clinical significance (2017) *HUM PATHOL*, 70, 6-13.

**IF: 3.125**

Garcia J., Lopez M., Lopez L., Bague S., Granell E., Quer M., Leon X., Validation of the pathological classification of lymph node metastasis for head and neck tumors according to the 8th edition of the TNM Classification of Malignant Tumors (2017) *ORAL ONCOL*, 70, 29-33.

**IF: 4.636**

Garcia-Sanz P., Trivino J.C., Mota A., Perez Lopez M., Colas E., Rojo-Sebastian A., Garcia A., Gatus S., Ruiz M., Prat J., Lopez-Lopez R., Abal M., Gil-Moreno A., Reventos J., Matias-Guiu X., Moreno-Bueno G., Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma (2017) *INT J CANCER*, 140 (7), 1551-1563.

**IF: 7.360**

Gronchi A., Ferrari S., Quagliuolo V., Broto J.M., Pousa A.L., Grignani G., Basso U., Blay J.-Y., Tendero O., Beveridge R.D., Ferraresi V., Lugowska I., Merlo D.F., Fontana V., Marchesi E., Donati D.M., Palassini E., Palmerini E., De Sanctis R., Morosi C., Stacchiotti S., Bague S., Coindre J.M., Dei Tos A.P., Picci P., Bruzzi P., Casali P.G., Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-ST5 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial (2017) *LANCET ONCOL*, 18 (6), 812-822.

**IF: 36.418**

Martel M., Alemany L., Taberna M., Mena M., Tous S., Bague S., Castellsague X., Quer M., Leon X., The role of HPV on the risk of second primary neoplasia in patients with oropharyngeal carcinoma (2017) *ORAL ONCOL*, 64, 37-43.

**IF: 4.636**

Prat J., Pathology of borderline and invasive cancers (2017) *BEST PRACT RES CL OB*, 41, 15-30.

**IF: 2.710**

Redondo A., Bague S., Bernabeu D., Ortiz-Cruz E., Valverde C., Alvarez R., Martinez-Trufero J., Lopez-Martin J.A., Correa R., Cruz J., Lopez-Pousa A., Santos A., Garcia Del Muro X., Martin-Broto J., Malignant bone tumors (other than Ewing's): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on

Sarcomas (GEIS) (2017) *CANCER CHEMOTH PHARM*, 80 (6), 1113-1131.

**IF: 2.808**

Sanchez E., Nieto J.C., Vidal S., Santiago A., Martinez X., Sancho F.J., Sancho-Bru P., Mirelis B., Corominola H., Juarez C., Manichanh C., Guarner C., Soriano G., Fermented milk containing *Lactobacillus paracasei* subsp. *paracasei* CNCM I-1518 reduces bacterial translocation in rats treated with carbon tetrachloride (2017) *SCI REP-UK*, 7.

**IF: 4.122**

Sanmartin E., Ortiz-Martinez F., Pomares-Navarro E., Garcia-Martinez A., Rodrigo-Banos M., Garcia-Escolano M., Andres L., Lerma E., Aranda F.I., Martinez-Peinado P., Sempere-Ortells J.M., Peiro G., CD44 induces FOXP3 expression and is related with favorable outcome in breast carcinoma (2017) *VIRCHOWS ARCH*, 470 (1), 81-90.

**IF: 2.936**

Sullivan I., Salazar J., Arqueros C., Andres M., Sebio A., Majem M., Szafranska J., Martinez E., Paez D., Lopez-Pousa A., Baiget M., Barnadas A., KRAS genetic variant as a prognostic factor for recurrence in resectable non-small cell lung cancer (2017) *CLIN TRANSL ONCOL*, 19 (7), 884-890.

**IF: 2.392**